← Mechanisms of action
CSF2
SINGLE PROTEINHomo sapiens
Preferred name: Granulocyte-macrophage colony-stimulating factor ChEMBL ↗
Linked proteins
Drugs acting on this target (18)
| Active Pharmaceutical Ingredient | Mechanism Type ▲ | Approval Status | API Type | Mechanism of Action |
|---|---|---|---|---|
| talimogene laherparepvec (Imlygic) | Activator | approved | Biological | CSF2 activator |
| sargramostim (leukine) | Agonist | approved | Recombinant protein | CSF2 agonist |
| cSF-25 | Antagonist | experimental | mAb | GM-CSF |
| mavrilimumab | Antagonist | experimental | mAb | CSF2 antagonist |
| tj003234 | Antagonist | experimental | mAb | Granulocyte-macrophage colony-stimulating factor antagonist |
| dtgm fusion protein | Binding agent | experimental | Recombinant protein | CSF2 binding agent |
| gm-csf vaccine | Immunity, active | experimental | Biological | CSF2 immunity, active |
| vaccinia-gm-csf vaccine | Immunity, active | experimental | Vaccine | CSF2 immunity, active |
| anti-gm-csf monoclonal antibody | Inhibitor | experimental | mAb | CSF2 inhibitor |
| csl 311 | Inhibitor | experimental | mAb | CSF2 inhibitor |
| CSL311 | Inhibitor | experimental | mAb | CSF2 inhibitor |
| gimsilumab | Inhibitor | experimental | mAb | CSF2 inhibitor |
| lenzilumab | Inhibitor | experimental | mAb | CSF2 inhibitor |
| namilumab | Inhibitor | experimental | mAb | CSF2 inhibitor |
| otilimab | Inhibitor | experimental | mAb | CSF2 inhibitor |
| tj003234 | Inhibitor | experimental | mAb | CSF2 inhibitor |
| gm-csf plasmid | Supplementation | experimental | Gene therapy | CSF2 supplementation |
| pexastimogene devacirepvec | Vaccine antigen | experimental | Biological | Granulocyte-macrophage colony-stimulating factor vaccine antigen |